CycloSPORINE Ophthalmic Suspension
RxNorm 378766

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 378766 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: cycloSPORINE Ophthalmic Suspension.

The following semantic concepts and normalized strings are associated with this clinical entity:

TMSY
CycloSPORINE Ophthalmic Suspension
AUI:3724191
View
SCDF
Cyclosporine Ophthalmic Suspension
AUI:12263984
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

TMSYPrescribable

Tall Man Lettering Synonym (TMSY):
CycloSPORINE Ophthalmic Suspension
(Atom ID: 3724191)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
cycloSPORINE Ophthalmic Suspension
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
378766
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
3724191
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
378766
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SCDFPrescribable

Semantic Clinical Drug Form (SCDF):
Cyclosporine Ophthalmic Suspension
(Atom ID: 12263984)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
cyclosporine Ophthalmic Suspension
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
378766
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12263984
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDF
Semantic Clinical Drug Form (Ingredient + Dose Form)
Source Code
378766
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Cyclosporine Ophthalmic


Ophthalmic cyclosporine is used to increase tear production in people with dry eye disease. Cyclosporine is in a class of medications called immunomodulators. It works by decreasing swelling in the eye to allow for tear production.
[Learn More]


* Please review the disclaimer below.